Aims/hypothesis We sought to investigate the stimulation of islet regeneration by transplanted human umbilical cord blood (UCB) cells purified according to high aldehyde dehydrogenase (ALDH) activity (ALDH hi ), a conserved characteristic of multiple progenitor lineages. We hypothesised that direct intrapancreatic (iPan) delivery of ALDH hi progenitors would augment islet regeneration via timely and localised exposure to islet-regenerative stimuli. Methods Cells were purified from UCB based on flow cytometry for low ALDH activity (ALDH lo ) vs ALDH hi . UCB ALDH lo or ALDH hi cells were compared for surface marker expression, as well as haematopoietic, endothelial and multipotent stromal progenitor content in vitro. UCB ALDH lo or ALDH hi cells were i.v. or iPan injected into streptozotocin-treated non-obese diabetic/severe combined immune-deficient mice temporally monitored for blood glucose, serum insulin and glucose tolerance. Human cell recruitment and survival in the pancreas, insulin content, islet-associated cell proliferation and islet vascularisation were documented in situ.
progenitors would augment islet regeneration via timely and localised exposure to islet-regenerative stimuli. Methods Cells were purified from UCB based on flow cytometry for low ALDH activity (ALDH lo ) vs ALDH hi . UCB ALDH lo or ALDH hi cells were compared for surface marker expression, as well as haematopoietic, endothelial and multipotent stromal progenitor content in vitro. UCB ALDH lo or ALDH hi cells were i.v. or iPan injected into streptozotocin-treated non-obese diabetic/severe combined immune-deficient mice temporally monitored for blood glucose, serum insulin and glucose tolerance. Human cell recruitment and survival in the pancreas, insulin content, islet-associated cell proliferation and islet vascularisation were documented in situ.
Results UCB-derived ALDH hi cells were highly enriched for haematopoietic and endothelial progenitor frequency, and showed increased expression of progenitor and myeloid cell surface markers. Although i.v. transplantation of ALDH hi cells demonstrated low pancreas engraftment and only transient blood glucose lowering capacity, iPan injected ALDH hi cells reversed established hyperglycaemia, increased serum insulin and improved the response to a glucose challenge. iPan injected ALDH hi cells surrounded damaged islets at early time points and increased islet-associated cell proliferation, resulting in the recovery of beta cell mass. Conclusions/interpretation iPan delivery of UCB ALDH hi cells potentiated islet-associated cell proliferation, insulin production and islet revascularisation, resulting in the recovery of host islet function. Elucidation of the progenitor-specific pathways stimulated during islet regeneration may provide new approaches to promote islet expansion during diabetes. 
Introduction
Residual islet function in diabetes patients with disease duration of >50 years suggests that the stimulation of islet regeneration may represent a viable strategy for diabetes treatment [1] . There exists increasing evidence that bone marrow (BM)-derived cells promote islet recovery after transplantation [2] [3] [4] , and we have recently shown that the mechanisms of islet regeneration are modulated by the progenitor subtypes administered [5] . While transplanted human multipotent stromal cells stimulated the formation of small islets associated with ducts, i.v. transplanted BM with high aldehyde dehydrogenase (ALDH) activity (ALDH hi ) induced islet cell proliferation and led to the recovery of larger and highly perfused islets [5] . As a readily available alternative to BM, we postulated that transplantation of umbilical cord blood (UCB)-derived ALDH hi cells would stimulate islet expansion and vascularisation. Since human cell recruitment to the pancreas is inefficient following i.v. transplantation [5] , we intended to determine if UCB ALDH hi cells delivered directly to the pancreas would permit timely exposure to regenerative stimuli and potentiate the recovery of islet function.
Methods
Cell isolation and characterisation Human UCB was obtained by venipuncture after informed consent at the London Health Sciences Centre. Within 24 h, mononuclear cells were isolated by Ficoll-Hypaque centrifugation, and cells with low ALDH activity (ALDH lo ), as well as ALDH hi cells, were purified by cell sorting based on ALDH activity using Aldefluor reagent (Stem Cell Technologies, Vancouver, BC, Canada) as previously described [6] . ALDH lo and ALDH hi cells were characterised for mature haematopoietic and primitive progenitor marker expression, and colonyforming cell (CFC) assays were performed for haematopoietic, endothelial and multipotent stromal progenitor functions as previously described [7] .
Transplantation of hyperglycaemic mice Non-obese diabetic/ severe combined immune-deficient (NOD/SCID) mice (Jackson Laboratory, Bar Harbor, ME, USA) were injected with streptozotocin (STZ) 35 mg/kg per day i.p. on days 1-5. At day 10, mice were sublethally irradiated (300 cGy) to reduce residual innate immunity and transplanted by tail vein or intrapancreatic (iPan) injection with PBS or 2×10 5 
ALDH
lo or ALDH hi cells from a fresh UCB sample. For iPan injections, mice were anaesthetised, the pancreas and spleen exposed, and cells were microinjected (10 μl) into the splenic portion of the pancreas. Non-fasted blood glucose was monitored weekly. Twenty-four hours prior to being killed, each mouse received 200 μg 5-ethynyl-2′-deoxyuridine (EdU), and a fasted (4 h) glucose tolerance test (2.0 g/kg glucose) was performed for a duration of 2 h. Serum was collected for insulin ELISA (Alpco, Salem, NH, USA). BM and pancreas were analysed for human cells by flow cytometry as previously described [5, 7] .
Immunohistochemistry Frozen pancreas sections were stained for immunofluorescent analyses to detect murine insulin with human cell engraftment (HLA-A,B,C), blood vessel density (von Willebrand factor; vWF) and EdU incorporation as previously described [5] . Table 1 ). In contrast to BM ALDH hi cells that possessed CFC capacity for all three-progenitor lineages [7] , UCB ALDH hi cells were enriched for multipotent haematopoietic and endothelial CFC (ESM Fig. 1a-e) , but did not establish multipotent stromal colonies (ESM Fig. 1c, f) hi cells on day 10, blood glucose was transiently reduced in comparison with that of PBS controls. However, from days 17 to 42, blood glucose gradually increased towards severe hyperglycaemia (>20 mmol/l; Fig. 1a ). Serum insulin (Fig. 1b) and response to glucose challenge (Fig. 1c) at day 42 were low for all i.v. transplanted groups. By contrast, iPan delivery of UCB ALDH hi cells reduced hyperglycaemia within 7 days ( * p<0.05), and blood glucose remained lower than pretransplant levels for >1 month (Fig. 1d) , indicating immediate and stable recovery from established hyperglycaemia. Compared with mice iPaninjected with PBS or ALDH lo cells, iPan ALDH hi transplanted mice showed increased serum insulin (Fig. 1e) and improved response to glucose challenge at day 42 (Fig. 1f) .
Results

UCB
iPan delivery of UCB ALDH hi cells increased islet number, size and vascularisation We postulated that iPan delivery of UCB ALDH hi cells would augment pancreas islet content. Compared with delivery-matched PBS or ALDH lo cells, iPan injection of ALDH hi cells increased both the number and size of islets, and augmented total beta cell mass (Fig. 1g-i) . Furthermore, islet size and total beta cell mass were increased compared with i.v. injection of ALDH hi cells ( * p<0.05). Although i.v. delivery of ALDH hi cells modestly increased islet-associated vascularisation (Fig. 1j, l) , iPan delivery of ALDH hi cells further improved islet vascularisation (Fig. 1k, l) . These effects were observed despite lowfrequency human cell engraftment in the pancreas of mice i.v. injected (four of nine mice) or iPan injected (four of five mice) with ALDH hi cells at day 42 (ESM Fig. 2a-b) . By contrast, ALDH lo cells were rarely detected in the pancreas after i.v. or iPan injection. Only ALDH hi cell i.v. transplanted mice showed haematopoietic reconstitution in the murine BM (ESM Fig. 2c-d) . Collectively, these data suggested that further experiments were warranted to characterise islet regenerative processes in relation to human cell pancreatic engraftment at early time points (days 14-17).
iPan-injected UCB ALDH
hi cells surrounded islets and stimulated islet cell proliferation To investigate human cell engraftment during hyperglycaemic reduction, mouse pancreases were isolated at days 14 and 17 and stained for cells producing insulin and HLA-A,B,C. At day 14, HLA + cells were very infrequent or absent in mice iPan injected with ALDH lo cells (ESM Fig. 2e ). By contrast, iPan injected ALDH hi cells showed improved survival and HLA + cells were numerous throughout the pancreas (Fig. 2a) . By day 17, when insulin production was sufficient to clearly identify regenerating islets, iPan delivered ALDH hi cells were localised surrounding islets (Fig. 2b) . Although few human cells remained at day 42 (arrows, Fig. 2c ), HLA + cells never produced insulin (Fig. 2a-c) . At days 14 and 17, human cell engraftment was not detected in the pancreas of any i.v. transplanted mice (data not shown). These data suggested that improved ALDH hi cell survival and recruitment to islets correlated with the temporal recovery of insulin production.
Next we assessed islet-associated cell proliferation using EdU labelling 24 h prior to sacrifice. While islet-associated proliferation was minimal in mice iPan injected with ALDH lo cells (ESM Fig. 2f ), mice iPan injected with ALDH hi cells demonstrated EdU labeling in both insulin − (arrowheads) and insulin + cells (arrows, Fig. 2d, e) . By day 17, the percentage of EdU + cells within islets was increased (Fig. 2f) hi transplanted mice showed an increase in non-fasted serum insulin (Fig. 2g, i) . However, serum insulin levels remained below threefold lower than citric acid buffer controls. Although iPan transplanted mice did not demonstrate a measurable response to glucose bolus at day 14 (Fig. 2h) , iPan ALDH hi transplanted mice demonstrated improved glucose tolerance by day 17 (Fig. 2j) . Collectively, these data suggested that within 4-7 days of iPan administration, increased ALDH hi cells surrounding islets correlated with increased proliferation of insulin + and insulin − cells, resulting in augmented insulin production and improved endocrine functions.
Discussion
This study demonstrates the capacity of UCB-derived ALDH hi cells to promote islet regeneration when transplanted directly into the murine pancreas. UCB ALDH hi cells represented a heterogeneous mixture of myeloid cells and haematopoietic/endothelial progenitors readily available for the development of novel cellular therapies for type 1 or type 2 diabetes through the recent establishment of UCB registries for allogeneic transplantation. While i.v. transplantation of UCB ALDH hi cells leads to minimal recovery of islet function, iPan delivery of UCB ALDH hi cells leads to reversal of established hyperglycaemia, increased serum insulin and improved glucose tolerance within 7 days of transplantation. To our knowledge this work represents the first report documenting potent islet recovery after iPan delivery of clinically applicable progenitors isolated from human UCB.
Islet cell proliferation correlated with the presence of UCB ALDH hi cells surrounding damaged islets, and islet number, size and vascularisation were increased 1 month post-transplantation. Although iPan injected ALDH lo cells were occasionally detected in the pancreas at early time points, these cells failed to induce islet-associated proliferation and subsequent recovery of function. Thus, islet regeneration was promoted after timely local exposure to ALDH hi cells, suggesting that islet proliferative or proangiogenic stimuli were provided specifically by iPan injected ALDH hi cells. Clinical evidence suggests that strategies employing BM or UCB stem cells can potentially benefit diabetic patients via beta cell regenerative or immunomodulatory mechanisms [8, 9] . However, Haller and colleagues recently reported that i.v. infusion of unfractionated UCB cells induced changes in regulatory T lymphocyte frequency but failed to preserve C-peptide [9] . Although our study did not directly address potential immunomodulatory mechanisms, or the activation of putative islet-derived beta cell precursors that may survive STZ toxicity [10] , these experiments establish proof of concept that iPan delivery of purified ALDH hi progenitor cells can formulate a regenerative niche that impacts the behaviour and function of regenerating host islets. Further investigation is warranted to elucidate the molecular pathways activated in signal-receiving beta cells or beta cell precursors during ALDH hi cell-stimulated islet regeneration, as iPan delivery of UCB ALDH hi cells may represent a viable strategy to 'tip the balance' in favour of islet expansion vs destruction during diabetes.
